Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29773956 | 1.00 | OPRM1 (0.41) | OPRM1HPGDSMN1; SMN2DGAT1PTPRC | |
| SCHEMBL9957429 | 0.85 | PTPRC (0.47) | HPGDSMN1; SMN2DGAT1PTPRCBCHE | |
| SCHEMBL9957560 | 0.85 | SMN1; SMN2 (0.46) | OPRM1HPGDSMN1; SMN2MAPTTP53 | |
| SCHEMBL9961080 | 0.78 | HDAC3 (0.35) | OPRM1SMN1; SMN2BCHE | |
| SCHEMBL4255873 | 0.76 | SMN1; SMN2 (0.52) | HPGDSMN1; SMN2DGAT1MAPTALDH1A1 | |
| SCHEMBL15259131 | 0.75 | NAMPT (0.52) | HPGDSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL23166736 | 0.75 | SMN1; SMN2 (0.41) | HPGDSMN1; SMN2 | |
| SCHEMBL29851760 | 0.75 | SMN1; SMN2 (0.41) | HPGDSMN1; SMN2 | |
| SCHEMBL13699507 | 0.75 | TDP1 (0.50) | BCHECNR2SUCNR1IDO1 | |
| SCHEMBL21534023 | 0.75 | TDP1 (0.50) | BCHECNR2SUCNR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11406618-B2 | Polymer-des-ethyl sunitinib conjugates | NEKTAR THERAPEUTICS (US) | 2022-08-09 | — | — | US | disclosed |
| US-20190142798-A1 | POLYMER-DES-ETHYL SUNITINIB CONJUGATES | NEKTAR THERAPEUTICS | 2019-05-16 | — | — | US | disclosed |
| US-10220020-B2 | Polymer-des-ethyl sunitinib conjugates | NEKTAR THERAPEUTICS (US) | 2019-03-05 | — | — | US | disclosed |
| EP-2654797-B1 | POLYMER-DES-ETHYL SUNITINIB CONJUGATES | NEKTAR THERAPEUTICS (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20140039030-A1 | POLYMER-DES-ETHYL SUNITINIB CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-02-06 | — | — | US | disclosed |
| EP-2654797-A1 | POLYMER-DES-ETHYL SUNITINIB CONJUGATES | Nektar Therapeutics (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012088522-A1 | POLYMER-DES-ETHYL SUNITINIB CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10220020-B2 | Polymer-des-ethyl sunitinib conjugates | KDR, FLT4, FLT1 | OPRM1 3976/4885HPGD 1949/4885SMN1; SMN2 1646/4885 |
| US-11406618-B2 | Polymer-des-ethyl sunitinib conjugates | KDR, FLT4, FLT1 | OPRM1 3976/4885HPGD 1949/4885SMN1; SMN2 1646/4885 |
| US-20140039030-A1 | POLYMER-DES-ETHYL SUNITINIB CONJUGATES | KDR, FLT4, FLT1 | OPRM1 3976/4885HPGD 1949/4885SMN1; SMN2 1646/4885 |
| US-20190142798-A1 | POLYMER-DES-ETHYL SUNITINIB CONJUGATES | KDR, FLT4, FLT1 | OPRM1 3976/4885HPGD 1949/4885SMN1; SMN2 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.